MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Synucleinopathies"

  • 2019 International Congress

    Amplification of α-synuclein aggregates in cerebrospinal fluid by rapid ultrasonication-based assay

    K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, T. Ohmichi, Y. Nagai, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

    Objective: To apply an ultrasonication-based misfolded  protein amplification to the evaluation of α-synuclein aggregates in CSF, and to investigate their clinical significances in Parkinson’s disease…
  • 2019 International Congress

    Arterial spin labelling detects subcortical hypoperfusion in early drug-naïve patients with Parkinson’s disease

    SP. Caminiti, G. Pagano, G. Dervenoulas, T. Yousaf, H. Wilson, M. Politis (London, United Kingdom)

    Objective: We evaluated regional cerebral blood flow (CBF) levels in a cohort of early drug-naïve patients with Parkinson’s disease, and we explored for associations between…
  • 2018 International Congress

    Development of anti-amyloid drugs for Parkinson’s disease by combination screening of high-throughput in vitro assay and phenotype-based C. elegans system

    K. Ikenaka, K. Araki, S. Sonoda, T. Takeuchi, Y. Nagai, Y. Goto, H. Mochizuki (Suita, Japan)

    Objective: To establish a new combination screening system consisted of high-throughput in vitro assay with phenotype-based in vivo assay and to develop anti-amyloid drugs truly…
  • 2018 International Congress

    Prevalence of REM Sleep Behavior Disorder in Sun City, Arizona

    D. Shprecher, A. Intorcia, M. Glass, J. Curry, J. Walker, B. Cutler, M. Callan, G. Serrano, N. Zhang, L. Sue, K. Davis, T. Beach (Sun City, AZ, USA)

    Objective: Determine prevalence of REM Sleep Behavior Disorder (RBD) in Sun City, Arizona Background: RBD is the strongest known clinical risk factor for neurodegenerative disorders…
  • 2018 International Congress

    Predicting Alpha-Synuclein Pathology by REM Sleep Behavior Disorder Diagnosis

    D. Shprecher, C. Adler, N. Zhang, J. Hentz, G. Serrano, B. Dugger, H. Shill, R. Savica, J. Caviness, M. Sabbagh, C. Belden, E. Driver-Dunckley, S. Mehta, L. Sue, K. Davis, E. Zamrini, T. Beach (Sun City, AZ, USA)

    Objective: Determine sensitivity, specificity and predictive value of clinician diagnosed probable REM sleep behavior disorder (PRBD) in predicting alpha-synuclein pathology. Background: Inability to accurately diagnose…
  • 2018 International Congress

    Longitudinal alpha-synuclein in cerebrospinal fluid in early Parkinson’s disease, prodromal PD and healthy controls

    B. Mollenhauer, C. Caspell-Garcia, C. Coffey, P. Taylor, A. Singleton, L. Shaw, J. Trojanowski, M. Frasier, T. Simuni, A. Siderowf, K. Marek, D. Galasko (Kassel, Germany)

    Objective: To examine the longitudinal relationships between total alpha-synuclein (aSyn) changes in cerebrospinal fluid (CSF), clinical measures, and factors that may influence CSF aSyn in…
  • 2018 International Congress

    PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG supplementation as anti-aggregation-approach

    J. Levin, S. Maass, M. Schuberth, A. Giese, W. Oertel, W. Poewe, C. Trenkwalder, G. Wenning, U. Mansmann, M. Suedmeyer, K. Eggert, B. Mollenhauer, A. Lipp, M. Loehle, J. Classen, A. Muenchau, J. Kassubeck, G. Ebersbach, D. Berg, S. Egert, C. Eberhardt, F. Paul, K. Boetzel, B. Ertl-Wagner, H. Huppertz, I. Ricard, G. Hoeglinger (Munich, Germany)

    Objective: To evaluate the safety and tolerability of epigallocatechin gallate (EGCG) in high doses and its efficacy to slow down disease progression in patients with…
  • 2018 International Congress

    Incidence, prevalence and clinical features of sleep disorders in alphasynucleinopthies: A cohort study

    C. Borrue-Fernandez, J. Fernandez- Cuesta, MJ. Abenza Abildua (San Sebastian Reyes, Spain)

    Objective: Analyze the sleep disorders incidence, prevelence an clinical features depending on the time of evolution, depending on the type of alpha-synuclein, and the subtype…
  • 2018 International Congress

    Free-living gait in REM sleep behaviour disorder: Measures of prodromal Parkinson’s disease?

    S. Del Din, T. Barber, C. Lo, M. Rolinski, F. Baig, M. Hu, L. Rochester (Newcastle upon Tyne, United Kingdom)

    Objective: The aim of this study was to investigate if free-living gait monitoring can discriminate individuals with REM sleep behaviour disorder (RBD) from controls. Background:…
  • 2018 International Congress

    Early synaptic loss and synaptic instability in a mouse model of prodromal Parkinson’s disease

    Y. Hatanaka, R. Takahashi (Kyoto, Japan)

    Objective: In order to elucidate very early pathologis of Parkinson’s disease (PD), we focused on synaptic pathologies in a newly developed mouse model of prodromal…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley